Professor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board
Why now
Thesis: Private biotech advisory news, no investable signal
Catalyst to watch: Clinical trial data for ISM-001
Main risk: Private company, preclinical-stage asset
Why it matters
A biotech advisory board appointment is early-stage and not financially material.
Details
Leading vascular biologists from Yale, Harvard, Uppsala and the University of Eastern Finland join Sessa to advise on the development of ISM-001, Isomab's first-in-class anti-VEGF-A165b antibody for chronic angina CAMBRIDGE, England, Sept. 29, 2026 /PRNewswire/ -- Isomab Ltd ("Isomab") a...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-29 12:03 UTC